Teva Sales Rise By 28%, Boosted By Cephalon Acquisition

Teva Pharmaceutical Industries announced a solid set of financials for their fourth quarter today. The financials were enhanced by sales of Teva’s multiple sclerosis drug, Copaxone, and from the contribution of recently-acquired Cephalon, which helped shift Teva further away from its original identity as a generic-drug maker. Teva’s net income increased by 23% to $1.40

Continue Reading